Gilead Sciences Beats U.S. in Billion-Dollar Trial Over Alleged HIV Drug Patent Violations

A Delaware federal court jury on Tuesday cleared Gilead Sciences of civil claims by the U.S. government that the company violated patents held by the Centers for Disease Control and Prevention for an HIV prevention drug.

The government sued Gilead in 2019, arguing that the company was profiting off CDC patents through the company’s sales of Truvada and Descovy, oral medications taken to prevent HIV infection.

But jurors after a multiday trial found that the government’s patent claims on the HIV prevention regimen called pre-exposure prophylaxis, or PrEP, were not valid.

Read the source article at cnbc.com